NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study

• click to rate

  Posted by Two Blokes Jun 25 - Filed in Stock - 3 views
  
  Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.